



# Svar Complement Portfolio

## SIMPLE AND OBJECTIVE METHODS TO AID COMPLEMENT RESEARCH & DEVELOPMENT

The Svar Complement portfolio consists of functional assessment assays for all three pathways and activity markers in simple and accurate ELISA format. All Svar complement assays are available through our Laboratory Services as bioanalytical studies in research and drug development.

- **REDUCED HANDS-ON-TIME**

The Svar Complement assays are flexible and easy to use enzyme immunoassays with ready to use reagents and short incubation times leading to reduced hands-on-time for the user.

- **EMERGING AREAS OF USE**

C4d is since long time widely used as a histology marker of complement activity in several diseases, especially conditions with renal involvement, investigation of solid organ grafts and a diagnostic tool to identify antibody-mediated rejection. C4d in plasma is now increasingly identified as a biomarker for complement activation and as a tool to predict and monitoring flares in several autoimmune conditions.


- **THE NEOEPITOPE ASSAY PRINCIPLE**

Like other activation products of the complement activation cascade, C4d is specifically measured by the neoepitope assay principle. Neoepitopes are epitopes hidden in the native component and being exposed on the surface of fragments formed during activation.

The Svar Complement C4d assay is based on the detection of the short linear C4d neoepitope exposed at the cleavage site of C4 after activation. This epitope is insensitive to repeated freeze – thaw cycles of samples.

*“C4d levels correlate with disease activity and rise before renal flares in lupus nephritis. C4d levels are more valuable than either C3 or C4 in predicting recurrence of renal flares, aiding clinicians in adjusting treatment in time” (Martin 2017)*

COMPLEMENT C4d	
<b>Product code</b>	COMPL C4d RUO
<b>Format &amp; Tests</b>	ELISA, Break apart 96 wells
<b>Range &amp; Units</b>	0-400 ng/ml, 6 calibrators, Ready to use
<b>Incubation Time &amp; Temp</b>	60-30-30 min, Room temperature
<b>Detection system</b>	450 nm
<b>Availability</b>	FOR RESEARCH USE ONLY. Not for use in diagnostic procedures



## REFERENCES

1. Ajona et al. Oncotarget. 2017 Dec 26;9(5):6346-6355
2. Blom et al. Mol Immunol. 2015 Aug;66(2):164-70
3. Cohen et al. Kidney Int. 2012 Apr;81(7):628-39
4. Gou et al. Kidney Int. 2013 Jan;83(1):129-37
5. Harboe et al, Adv Drug Deliv Rev. 2011 Sep 16;63(12):976-87
6. Martin et al. Arthritis Res Ther. 2017 Dec 6;19(1):266
7. Mollnes et al, Mol Immunol. 2007 Sep;44(16):3838-49
8. Nilsson et al. Clin Dev Immunol. 2012;2012:962702
9. Okroj et al. Arthritis Res Ther. 2016 Nov 18;18(1):267
10. Prohászka et al. Mol Immunol. 2018 Oct;102:84-88